A detailed history of Chesapeake Asset Management LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Chesapeake Asset Management LLC holds 6,567 shares of ABBV stock, worth $1.54 Million. This represents 1.34% of its overall portfolio holdings.

Number of Shares
6,567
Previous 6,561 0.09%
Holding current value
$1.54 Million
Previous $1.52 Million 1.12%
% of portfolio
1.34%
Previous 1.42%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 08, 2026

BUY
$211.96 - $244.38 $1,271 - $1,466
6 Added 0.09%
6,567 $1.54 Million
Q3 2025

Oct 17, 2025

SELL
$184.85 - $231.54 $19,224 - $24,080
-104 Reduced 1.56%
6,561 $1.52 Million
Q2 2025

Oct 15, 2025

BUY
$170.16 - $206.27 $1.13 Million - $1.37 Million
6,665 New
6,665 $1.24 Million
Q1 2025

Jan 05, 2026

BUY
$169.2 - $216.66 $42,130 - $53,948
249 Added 3.88%
6,665 $1.4 Billion
Q4 2024

Jan 05, 2026

SELL
$164.99 - $203.87 $8,909 - $11,008
-54 Reduced 0.83%
6,416 $1.14 Billion
Q3 2024

Jan 05, 2026

BUY
$163.84 - $199.33 $16,056 - $19,534
98 Added 1.54%
6,470 $1.28 Billion
Q2 2024

Jan 05, 2026

SELL
$154.79 - $180.76 $29,255 - $34,163
-189 Reduced 2.88%
6,372 $1.09 Billion
Q1 2024

Jan 05, 2026

SELL
$159.82 - $182.1 $1.03 Million - $1.17 Million
-6,436 Reduced 49.47%
6,573 $1.2 Billion
Q4 2023

Jan 05, 2026

SELL
$137.6 - $154.97 $74,579 - $83,993
-542 Reduced 4.0%
13,009 $2.02 Billion
Q3 2023

Jan 05, 2026

BUY
$133.59 - $154.65 $310,062 - $358,942
2,321 Added 20.67%
13,551 $2.02 Billion
Q2 2023

Jan 05, 2026

BUY
$132.51 - $164.9 $195,849 - $243,722
1,478 Added 15.16%
11,230 $1.51 Billion
Q1 2023

Jan 05, 2026

BUY
$144.61 - $166.54 $461,450 - $531,429
3,191 Added 48.64%
9,752 $1.55 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Chesapeake Asset Management LLC Portfolio

Follow Chesapeake Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chesapeake Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chesapeake Asset Management LLC with notifications on news.